THNR

Amplify Weight Loss Drug & Treatment ETF
THNR
Market cap $4.69M

26.04 USD

-0.21

0.80%

Updated Oct 22, 10:07 AM EDT

1 day

-0.80%

5 days

-1.10%

1 month

-3.98%

3 months

-0.61%

6 months

2.52%

Year to date

2.52%

1 year

2.52%

5 years

2.52%

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

23.23% more ownership

Funds ownership: 0% [Q1] → 23.23% (+23.23%) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for THNR.

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Tap the Weight-Loss Drug Market With These ETFs

Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.

Tap the Weight-Loss Drug Market With These ETFs

Disruptive Theme of the Week: Playing Defense

When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.

Disruptive Theme of the Week: Playing Defense

Zacks Investment Research

ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.

ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

SILJ, HACK, THNR: Trends in Thematic Investing

Amplify Junior Silver Miners ETF (SILJ) is up 28% year-to-date. Christian Magoon discusses the outlook for cybersecurity stocks, as Amplify's Cybersecurity ETF (HACK) is up 8% year-to-date.

SILJ, HACK, THNR: Trends in Thematic Investing

Top Themes in the First Half of 2024: Crypto, Chips, Ships & Silver

After a torrid risk-on run in the first quarter of 2024, markets cooled off a bit but ended the half still positive with mid-double-digit returns. Technology themes such as cryptocurrency and artificial intelligence helped propel markets higher.

Top Themes in the First Half of 2024: Crypto, Chips, Ships & Silver

Why Investors Haven't Feasted on Two New Weight-Loss ETFs

Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.

Why Investors Haven't Feasted on Two New Weight-Loss ETFs

Finding Opportunity in Unloved Healthcare ETFs

Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?

Finding Opportunity in Unloved Healthcare ETFs

Zacks Investment Research

Play These New ETFs to Tap Lucrative Weight Loss Drug Market

Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.

Play These New ETFs to Tap Lucrative Weight Loss Drug Market

Amplify Debuts New Weight Loss Drug ETF

On Tuesday, Amplify entered the weight loss ETF space with the launch of the Amplify Weight Loss Drug & Treatment ETF (THNR). THNR operates with a net expense ratio of 0.59%.

Amplify Debuts New Weight Loss Drug ETF

See News Rankings

Charts implemented using Lightweight Charts™